ArriVent BioPharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Operating income | -$177.5 | -$94.3 | -$74.6 | — |
| Net income | -$166.3 | -$80.5 | -$69.3 | — |
Shares outstanding 49.3M · Free float 70.0%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.